Kernodle & Katon Asset Management Group’s Teva Pharmaceuticals TEVA Stock Holding History

Kernodle & Katon Asset Management Group’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	$16K	Hold	507	–	–	0.01%	207
2016 Q4	$18K	Hold	507	–	–	0.01%	202
2016 Q3	$23K	Hold	507	–	–	0.01%	217
2016 Q2	$25K	Hold	507	–	–	0.02%	174
2016 Q1	$27K	Hold	507	–	–	0.03%	154
2015 Q4	$33K	Buy	+507	New	+$31.3K	0.03%	145

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Kernodle & Katon Asset Management Group's TEVA Position: Q1 2017 in Review

Kernodle & Katon Asset Management Group held its Teva Pharmaceuticals (TEVA) position steady in Q1 2017 at 507 shares worth $16K. The position accounts for 0.01% of the portfolio, ranked #207.

Kernodle & Katon Asset Management Group first reported a position in TEVA in Q4 2015 and has held it in 6 quarters since. The position peaked at $33K in Q4 2015. 686 funds tracked by Wall St. Rank hold TEVA as of Q1 2017.

Kernodle & Katon Asset Management Group held 507 shares of Teva Pharmaceuticals worth $16K as of Q1 2017.
Kernodle & Katon Asset Management Group left its Teva Pharmaceuticals share count unchanged in Q1 2017.
Teva Pharmaceuticals made up 0.01% of Kernodle & Katon Asset Management Group's portfolio in Q1 2017, its #207 holding.
Kernodle & Katon Asset Management Group first reported a position in Teva Pharmaceuticals in Q4 2015 and has held it in 6 quarters since.
Kernodle & Katon Asset Management Group's Teva Pharmaceuticals position peaked at $33K in Q4 2015.
686 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2017.

Based on Kernodle & Katon Asset Management Group's 13F filing for Q1 2017, filed 12 May 2017.